NVST Quote, Financials, Valuation and Earnings

Biolase has a net margin of 2.92% compared to Envista Holdings's net margin of -13.16%. Envista Holdings's return on equity of -34.78% beat Biolase's return on equity of -21668.17%.

Envista Holdings has a consensus price target of $19.04, signalling upside risk potential of 3.15%. On the other hand Biolase has an analysts' consensus of $1.2000 which suggests that it could grow by 18947.62%. Given that Biolase has higher upside potential than Envista Holdings, analysts believe Biolase is more attractive than Envista Holdings.

Envista Holdings has a beta of 0.975, which suggesting that the stock is 2.472% less volatile than S&P 500. In comparison Biolase has a beta of 0.016, suggesting its less volatile than the S&P 500 by 98.394%.

Envista Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biolase offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Envista Holdings pays -- of its earnings as a dividend. Biolase pays out -- of its earnings as a dividend.

Envista Holdings quarterly revenues are $616.9M, which are larger than Biolase quarterly revenues of $10.9M. Envista Holdings's net income of $18M is higher than Biolase's net income of -$1.4M. Notably, Envista Holdings's price-to-earnings ratio is -- while Biolase's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Envista Holdings is 1.27x versus 0.01x for Biolase. Usually stocks with elevated PS ratios are considered overvalued.

Milestone Scientific has a net margin of 2.92% compared to Envista Holdings's net margin of -89.35%. Envista Holdings's return on equity of -34.78% beat Milestone Scientific's return on equity of -79.98%.

Envista Holdings has a consensus price target of $19.04, signalling upside risk potential of 3.15%. On the other hand Milestone Scientific has an analysts' consensus of $2.13 which suggests that it could grow by 122.51%. Given that Milestone Scientific has higher upside potential than Envista Holdings, analysts believe Milestone Scientific is more attractive than Envista Holdings.

Envista Holdings has a beta of 0.975, which suggesting that the stock is 2.472% less volatile than S&P 500. In comparison Milestone Scientific has a beta of 0.934, suggesting its less volatile than the S&P 500 by 6.585%.

Envista Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Envista Holdings pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

Envista Holdings quarterly revenues are $616.9M, which are larger than Milestone Scientific quarterly revenues of $2.2M. Envista Holdings's net income of $18M is higher than Milestone Scientific's net income of -$2M. Notably, Envista Holdings's price-to-earnings ratio is -- while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Envista Holdings is 1.27x versus 8.88x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Solventum has a net margin of 2.92% compared to Envista Holdings's net margin of 6.62%. Envista Holdings's return on equity of -34.78% beat Solventum's return on equity of 11.75%.

Envista Holdings has a consensus price target of $19.04, signalling upside risk potential of 3.15%. On the other hand Solventum has an analysts' consensus of $81.27 which suggests that it could grow by 11.92%. Given that Solventum has higher upside potential than Envista Holdings, analysts believe Solventum is more attractive than Envista Holdings.

Envista Holdings has a beta of 0.975, which suggesting that the stock is 2.472% less volatile than S&P 500. In comparison Solventum has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Envista Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Envista Holdings pays -- of its earnings as a dividend. Solventum pays out -- of its earnings as a dividend.

Envista Holdings quarterly revenues are $616.9M, which are smaller than Solventum quarterly revenues of $2.1B. Envista Holdings's net income of $18M is lower than Solventum's net income of $137M. Notably, Envista Holdings's price-to-earnings ratio is -- while Solventum's PE ratio is 33.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Envista Holdings is 1.27x versus 1.52x for Solventum. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona has a net margin of 2.92% compared to Envista Holdings's net margin of 2.28%. Envista Holdings's return on equity of -34.78% beat Dentsply Sirona's return on equity of -35.57%.

Envista Holdings has a consensus price target of $19.04, signalling upside risk potential of 3.15%. On the other hand Dentsply Sirona has an analysts' consensus of $18.14 which suggests that it could grow by 10.66%. Given that Dentsply Sirona has higher upside potential than Envista Holdings, analysts believe Dentsply Sirona is more attractive than Envista Holdings.

Envista Holdings has a beta of 0.975, which suggesting that the stock is 2.472% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.924, suggesting its less volatile than the S&P 500 by 7.642%.

Envista Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 3.92% to investors and pays a quarterly dividend of $0.16 per share. Envista Holdings pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.

Envista Holdings quarterly revenues are $616.9M, which are smaller than Dentsply Sirona quarterly revenues of $879M. Envista Holdings's net income of $18M is lower than Dentsply Sirona's net income of $20M. Notably, Envista Holdings's price-to-earnings ratio is -- while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Envista Holdings is 1.27x versus 0.88x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.